What is the share price of Haleos Labs Ltd (HALEOSLABS) today?
The share price of HALEOSLABS as on 5th December 2025 is ₹1335. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Haleos Labs Ltd (HALEOSLABS) share?
The past returns of Haleos Labs Ltd (HALEOSLABS) share are- Past 1 week: -1.66%
- Past 1 month: 11.05%
- Past 3 months: 20.12%
- Past 6 months: 3.75%
- Past 1 year: 14.40%
- Past 3 years: 107.33%
- Past 5 years: 92.32%
What are the peers or stocks similar to Haleos Labs Ltd (HALEOSLABS)?
The peers or stocks similar to Haleos Labs Ltd (HALEOSLABS) include:What is the dividend yield % of Haleos Labs Ltd (HALEOSLABS) share?
The current dividend yield of Haleos Labs Ltd (HALEOSLABS) is 0.11.What is the market cap of Haleos Labs Ltd (HALEOSLABS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Haleos Labs Ltd (HALEOSLABS) is ₹403.61 Cr as of 5th December 2025.What is the 52 week high and low of Haleos Labs Ltd (HALEOSLABS) share?
The 52-week high of Haleos Labs Ltd (HALEOSLABS) is ₹1680 and the 52-week low is ₹959.80.What is the PE and PB ratio of Haleos Labs Ltd (HALEOSLABS) stock?
The P/E (price-to-earnings) ratio of Haleos Labs Ltd (HALEOSLABS) is 20.07. The P/B (price-to-book) ratio is 1.90.Which sector does Haleos Labs Ltd (HALEOSLABS) belong to?
Haleos Labs Ltd (HALEOSLABS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Haleos Labs Ltd (HALEOSLABS) shares?
You can directly buy Haleos Labs Ltd (HALEOSLABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Haleos Labs Ltd
HALEOSLABS Share Price
1,335.001.51% (+19.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
HALEOSLABS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
HALEOSLABS Performance & Key Metrics
HALEOSLABS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 21.62 | 1.90 | 0.11% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
HALEOSLABS Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
HALEOSLABS Company Profile
Haleos Labs Ltd, formerly SMS Lifesciences India Ltd, manufactures active pharmaceutical ingredients (APIs) and intermediates including Ranitidine Hydrochloride, Famotidine, Sildenafil Citrate, and others, with manufacturing facilities in Kazipally and Jeedimetla and an R&D center in Sanath Nagar, Hyderabad.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
HALEOSLABS Forecast
HALEOSLABS Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
HALEOSLABS
HALEOSLABS
Income
Balance Sheet
Cash Flow
Annual Normal View
HALEOSLABS Income Statement
HALEOSLABS Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 380.36 | 263.06 | 267.37 | 364.50 | 320.98 | 309.79 | 349.59 | 341.40 | ||||||||
Raw Materials | 268.79 | 147.04 | 135.17 | 204.47 | 171.33 | 150.19 | 149.91 | 292.13 | ||||||||
| Power & Fuel Cost | 25.93 | 20.48 | 21.56 | 30.02 | 29.28 | 30.46 | 32.53 | |||||||||
| Employee Cost | 23.11 | 26.56 | 30.66 | 39.90 | 43.43 | 52.26 | 59.54 | |||||||||
| Selling & Administrative Expenses | 11.98 | 9.28 | 12.28 | 13.77 | 12.52 | 11.22 | 13.04 | |||||||||
| Operating & Other expenses | 13.28 | 32.02 | 35.68 | 27.37 | 30.18 | 30.61 | 44.61 | |||||||||
EBITDA | 37.27 | 27.68 | 32.02 | 48.97 | 34.24 | 35.05 | 49.96 | 49.27 | ||||||||
| Depreciation/Amortization | 6.38 | 7.86 | 7.86 | 10.01 | 10.79 | 14.94 | 15.00 | 15.27 | ||||||||
| PBIT | 30.89 | 19.82 | 24.16 | 38.96 | 23.45 | 20.11 | 34.96 | 34.00 | ||||||||
| Interest & Other Items | 5.51 | 5.15 | 4.60 | 6.23 | 6.87 | 10.26 | 8.77 | 7.66 | ||||||||
| PBT | 25.38 | 14.67 | 19.56 | 32.73 | 16.58 | 9.85 | 26.19 | 26.34 | ||||||||
| Taxes & Other Items | 7.54 | 4.49 | 6.02 | 7.41 | 5.13 | 0.75 | 6.08 | 7.67 | ||||||||
| Net Income | 17.84 | 10.18 | 13.54 | 25.32 | 11.45 | 9.10 | 20.11 | 18.67 | ||||||||
| EPS | 59.01 | 33.67 | 44.79 | 83.75 | 37.87 | 30.10 | 66.52 | 61.75 | ||||||||
| DPS | 1.50 | 0.00 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | ||||||||
| Payout ratio | 0.03 | 0.00 | 0.03 | 0.02 | 0.04 | 0.05 | 0.02 | 0.02 |
HALEOSLABS Company Updates
HALEOSLABS Stock Peers
HALEOSLABS Past Performance & Peer Comparison
HALEOSLABS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Haleos Labs Ltd | 20.07 | 1.90 | 0.11% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
HALEOSLABS Stock Price Comparison
Compare HALEOSLABS with any stock or ETFCompare HALEOSLABS with any stock or ETF
HALEOSLABS
HALEOSLABS Holdings
HALEOSLABS Shareholdings
HALEOSLABS Promoter Holdings Trend
HALEOSLABS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
HALEOSLABS Institutional Holdings Trend
HALEOSLABS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
HALEOSLABS Shareholding Pattern
HALEOSLABS Shareholding Pattern
HALEOSLABS Shareholding History
HALEOSLABS Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing HALEOSLABS stock
smallcases containing HALEOSLABS stock
Looks like this stock is not in any smallcase yet.
HALEOSLABS Events
HALEOSLABS Events
HALEOSLABS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HALEOSLABS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.12 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
HALEOSLABS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HALEOSLABS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.12 every year
HALEOSLABS Upcoming Dividends
HALEOSLABS Upcoming Dividends
No upcoming dividends are available
HALEOSLABS Past Dividends
HALEOSLABS Past Dividends
Cash Dividend
Ex DateEx DateSep 24, 2025
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 24, 2025
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 20, 2021
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 20, 2021
HALEOSLABS Stock News & Opinions
HALEOSLABS Stock News & Opinions
Articles & Videos
Earnings
SMS Lifesciences India consolidated net profit rises 30.62% in the September 2025 quarter
Net profit of SMS Lifesciences India rose 30.62% to Rs 6.10 crore in the quarter ended September 2025 as against Rs 4.67 crore during the previous quarter ended September 2024. Sales rose 3.71% to Rs 81.37 crore in the quarter ended September 2025 as against Rs 78.46 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales81.3778.46 4 OPM %16.6810.91 - PBDT12.388.47 46 PBT8.494.70 81 NP6.104.67 31 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
SMS LifeSciences India announces board meeting date
SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
SMS LifeSciences India AGM scheduled
SMS LifeSciences India announced that the 19th Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
SMS Lifesciences India consolidated net profit declines 40.57% in the June 2025 quarter
Net profit of SMS Lifesciences India declined 40.57% to Rs 4.16 crore in the quarter ended June 2025 as against Rs 7.00 crore during the previous quarter ended June 2024. Sales declined 10.86% to Rs 82.50 crore in the quarter ended June 2025 as against Rs 92.55 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales82.5092.55 -11 OPM %14.1917.59 - PBDT10.8414.32 -24 PBT7.0210.64 -34 NP4.167.00 -41 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
SMS LifeSciences India to table results
SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 11 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
SMS Lifesciences India Ltd leads gainers in 'B' group
Magellanic Cloud Ltd, Fischer Medical Ventures Ltd, Global Surfaces Ltd and 20 Microns Ltd are among the other gainers in the BSE's 'B' group today, 16 July 2025.SMS Lifesciences India Ltd spiked 18.29% to Rs 1353 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 4218 shares were traded on the counter so far as against the average daily volumes of 126 shares in the past one month. Magellanic Cloud Ltd soared 17.47% to Rs 95.74. The stock was the second biggest gainer in 'B' group. On the BSE, 50.96 lakh shares were traded on the counter so far as against the average daily volumes of 4.26 lakh shares in the past one month. Fischer Medical Ventures Ltd surged 14.64% to Rs 912. The stock was the third biggest gainer in 'B' group. On the BSE, 18423 shares were traded on the counter so far as against the average daily volumes of 10951 shares in the past one month. Global Surfaces Ltd gained 13.16% to Rs 126. The stock was the fourth biggest gainer in 'B' group. On the BSE, 2.12 lakh shares were traded on the counter so far as against the average daily volumes of 8209 shares in the past one month. 20 Microns Ltd jumped 12.45% to Rs 253.35. The stock was the fifth biggest gainer in 'B' group. On the BSE, 2.23 lakh shares were traded on the counter so far as against the average daily volumes of 10198 shares in the past one month. Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
SMS Lifesciences India consolidated net profit declines 49.66% in the March 2025 quarter
Net profit of SMS Lifesciences India declined 49.66% to Rs 2.97 crore in the quarter ended March 2025 as against Rs 5.90 crore during the previous quarter ended March 2024. Sales declined 0.98% to Rs 89.11 crore in the quarter ended March 2025 as against Rs 89.99 crore during the previous quarter ended March 2024. For the full year,net profit rose 121.23% to Rs 20.11 crore in the year ended March 2025 as against Rs 9.09 crore during the previous year ended March 2024. Sales rose 12.67% to Rs 344.72 crore in the year ended March 2025 as against Rs 305.96 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales89.1189.99 -1 344.72305.96 13 OPM %8.3312.62 -13.0710.17 - PBDT7.7310.88 -29 41.1924.78 66 PBT3.937.10 -45 26.199.85 166 NP2.975.90 -50 20.119.09 121 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Board of SMS LifeSciences India recommends final dividend
SMS LifeSciences India announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 15%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
SMS LifeSciences India to announce Quarterly Result
SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
SMS Lifesciences India spurts as Q3 PAT jumps 18% YoY to Rs 5 cr
Revenue from operations was at Rs 84.60 crore in the third quarter of FY25, marking a growth of 17.41% compared with Rs 72.05 crore in Q3 FY24. In Q3 FY25, the profit before tax (PBT) spiked 81.36% year on year (YoY) to Rs 6.91 crore. Total expenses added 12.96% YoY to Rs 77.74 crore in the quarter ended 31 December 2024. Cost of materials consumed was at Rs 39.43 crore (up 0.61% YoY), and employee benefits expense was at Rs 14.60 crore (up 9.69% YoY) during the period under review. On a nine-month basis, the company reported consolidated net profit of Rs 15.24 crore in 9M FY25, compared with net loss of Rs 0.14 crore posted in 9M FY24. Revenue from operations jumped 18.35% YoY to Rs 255.61 crore in 9M FY25. Meanwhile, the board has approved the reappointment of Veeravenkata Satyanarayana Murthy Talluri as managing director (MD) of the company for a further period of 3 consecutive year's w.e.f. 1 June 2025. SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents, and generally dealing with all types of organic & inorganic chemicals, pharmaceuticals, active pharmaceutical ingredients (API), and intermediates. Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.85%, vs industry avg of 10.04%
Over the last 5 years, market share decreased from 0.1% to 0.08%
Over the last 5 years, net income has grown at a yearly rate of 14.59%, vs industry avg of 20.02%